OMER Jan 2025 5.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:38AM EDT
| Previous close | 0.9000 |
| Open | 0.7500 |
| Bid | 0.5500 |
| Ask | 0.8000 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.35k |
- GuruFocus.com
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
Business WireOmeros Corporation Reports First Quarter 2024 Financial Results
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include:
© 2024 Yahoo. All rights reserved.